Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Has Johnson & Johnson (JNJ) Become the Perfect Stock?

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?

One thing’s for sure: You’ll never discover truly great investments unless you actively look for them. Let’s discuss the ideal qualities of a perfect stock, and then decide whether Johnson & Johnson (NYSE:JNJ) fits the bill.

The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it’s certainly a better sign than a stagnant top line.
  • Margins. Higher sales mean nothing if a company can’t produce profits from them. Strong margins ensure that the company can turn revenue into profit.
  • Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management’s attention. Companies with strong balance sheets don’t have to worry about the distraction of debt.
  • Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
  • Valuation. You can’t afford to pay too much for even the best companies. By using normalized figures, you can see how a stock’s simple earnings multiple fits into a longer-term context.
  • Dividends. For tangible proof of profits, a check to shareholders every three months can’t be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let’s take a closer look at Johnson & Johnson.

Factor What We Want to See Actual Pass or Fail?
Growth 5-year annual revenue growth > 15% 1.9% Fail
1-year revenue growth > 12% 3.4% Fail
Margins Gross margin > 35% 67.8% Pass
Net margin > 15% 16.1% Pass
Balance sheet Debt to equity < 50% 26.4% Pass
Current ratio > 1.3 1.87 Pass
Opportunities Return on equity > 15% 17.4% Pass
Valuation Normalized P/E < 20 22.37 Fail
Dividends Current yield > 2% 3.2% Pass
5-year dividend growth > 10% 8.4% Fail
Total score 6 out of 10

Source: S&P Capital IQ. Total score = number of passes.

Since we looked at Johnson & Johnson last year, the company gained back one of the three points it lost from 2011 to 2012. Rising margins brought on the improvement, and the shares have responded well, climbing almost 20% over the past year.

Most investors think of Johnson & Johnson’s consumer products as the leading edge of its massive health-care business. But what elevated J&J into the ranks of the Dow Jones Industrials is its diverse set of larger segments, which include both pharmaceutical development and medical-device manufacturing.

In fact, J&J’s pharmaceutical business is well-poised to challenge other industry leaders. With the company having relatively little exposure to patent-cliff issues, J&J is taking aim at rivals’ blockbuster drugs. For instance, its Invokana drug to treat Type 2 diabetes proved itself against Merck & Co., Inc. (NYSE:MRK)‘s Januvia, giving it the inside track to become the first FDA-approved SGLT2 inhibitor. Meanwhile, sales of J&J’s anti-inflammatory Stelara hit $1 billion in 2012, and with the drug showing significant improvement compared to Amgen, Inc. (NASDAQ:AMGN) and Pfizer Inc. (NYSE:PFE)‘s Enbrel, it has even more potential to grow.

The big question facing J&J, though, is whether it should follow the trend of other major pharmaceutical companies and break itself into its component parts. For the most part, CEO Alex Gorsky seems to like the company’s conglomerate nature, although he may be open to minor strategic moves such as selling off its diagnostics business.

For J&J to improve, it needs to get its earnings growing a bit faster and produce a little more dividend growth. Blockbuster drugs might be just the ticket to the success J&J needs to get closer to perfection.

The article Has Johnson & Johnson Become the Perfect Stock? originally appeared on Fool.com and is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!